Format

Send to

Choose Destination
Braz J Microbiol. 2016 Jan-Mar;47(1):172-6. doi: 10.1016/j.bjm.2015.02.001. Epub 2016 Jan 27.

Rapid detection of Candida species in bronchoalveolar lavage fluid from patients with pulmonary symptoms.

Author information

1
Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Parasitology and Mycology, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2
Department of Biotechnology, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita-shi, Osaka 565-0871, Japan.
3
Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran; CBS-KNAW, Utrecht, The Netherlands; Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands.
4
Department of Medical Parasitology and Mycology, School of Medicine and Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: dr.rasoul_mohammadi@yahoo.com.

Abstract

Candida species, especially C. albicans, are commensals on human mucosal surfaces, but are increasingly becoming one of the important invasive pathogens as seen by a rise in its prevalence in immunocompromised patients and in antibiotic consumption. Thus, an accurate identification of Candida species in patients with pulmonary symptoms can provide important information for effective treatment. A total of 75 clinical isolates of Candida species were obtained from the bronchoalveolar lavage fluid of both immunocompromised and immunocompetent patients with pulmonary symptoms. Candida cultures were identified based on nuclear ribosomal Internal Transcribed Spacer (ITS1-ITS2 rDNA) sequence analysis by polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP). Molecular identification indicated that the isolates belonged predominantly to C. albicans (52%), followed by C. tropicalis (24%), C. glabrata (14.7%), C. krusei (5.3%), C. parapsilosis (1.3%), C. kefyr (1.3%) and C. guilliermondii (1.3%). Given the increasing complexity of disease profiles and their management regimens in diverse patients, rapid and accurate identification of Candida species can lead to timely and appropriate antifungal therapy.

KEYWORDS:

Candida; PCR-RFLP; Pulmonary

PMID:
26887241
PMCID:
PMC4822774
DOI:
10.1016/j.bjm.2015.02.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center